1. Seebacher C, Bouchara JP, Mignon B. Updates on the Epidemiology of Dermatophyte Infections. Mycopathologia. 2008;166:335-52. DOI:10.1007/s11046-008-9100-9
2. Leung AK, Barankin B, Lam JM, et al. Tinea pedis: an updated review. Drugs Context. 2023;12:2023-5-1. DOI:10.7573/dic.2023-5-1
3. Nussipov Y, Markabayeva A, Gianfaldoni S, et al. Clinical and Epidemiological Features of Dermatophyte Infections in Almaty, Kazakhstan. Open Access Maced J Med Sci. 2017;5(4):409-13. DOI:10.3889/oamjms.2017.124
4. Ziółkowska G, Nowakiewicz A, Gnat S, et al. Molecular identification and classification of Trichophyton mentagrophytes complex strains isolated fr om humans and selected animal species. Mycoses. 2015;58(3):119-26. DOI:10.1111/myc.12284
5. Deng R, Wang X, Li R. Dermatophyte infection: from fungal pathogenicity to host immune responses. Front Immunol. 2023;14:1285887. DOI:10.3389/fimmu.2023.1285887
6. Uhrlaß S, Verma SB, Gräser Y, et al. Trichophyton indotineae – An Emerging Pathogen Causing Recalcitrant Dermatophytoses in India and Worldwide – A Multidimensional Perspective. J Fungi (Basel). 2022;8(7):757. DOI:10.3390/jof8070757
7. Shaw D, Singh S, Dogra S, et al. MIC and Upper Lim it of Wild-Type Distribution for 13 Antifungal Agents against a Trichophyton mentagrophytes-Trichophyton interdigitale Complex of Indian Origin. Antimicrob Agents Chemother. 2020;64(4):e01964-19. DOI:10.1128/AAC.01964-19
8. Garcia-Rubio R, Cuenca-Estrella M, Mellado E. Triazole Resistance in Aspergillus Species: An Emerging Problem. Drugs. 2017;77(6):599-613. DOI:10.1007/s40265-017-0714-4
9. Gupta AK, Stec N, Summerbell RC, et al. Onychomycosis: a review. J Eur Acad Dermatol Venereol. 2020;34(9):1972-90. DOI:10.1111/jdv.16394
10. Sahni K, Singh S, Dogra S. Newer Topical Treatments in Skin and Nail Dermatophyte Infections. Indian Dermatol Online J. 2018;9(3):149-58. DOI:10.4103/idoj.IDOJ_281_17
11. Jiang Y, Luo W, Verweij PE, et al. Regional Differences in Antifungal Susceptibility of the Prevalent Dermatophyte Trichophyton rubrum. Mycopathologia. 2021;186(1):53-70. DOI:10.1007/s11046-020-00515-z
12. Rotta I, Ziegelmann PK, Otuki MF, et al. Efficacy of topical antifungals in the treatment of dermatophytosis: a mixed-treatment comparison meta-analysis involving 14 treatments. JAMA Dermatol. 2013;149(3):341-9. DOI:10.1001/jamadermatol.2013
13. Sahoo AK, Mahajan R. Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review. Indian Dermatol Online J. 2016;7(2):77-86.
DOI:10.4103/2229-5178.178099
14. Gupta AK, Ryder JE, Cooper EA. Naftifine: a review. J Cutan Med Surg. 2008;12(2):51-8. DOI:10.2310/7750.2008.06009
15. Vlahovic TC. The Role of Naftifine HCl 2% Gel and Cream in Treating Moccasin Tinea Pedis. J Drugs Dermatol. 2016;15(2 Suppl.):s56-9.
16. Матушевская Е.В., Свирщевская Е.В. Нафтифин в терапии грибковых инфекций кожи: 40 лет успеха. Вестник дерматологии и венерологии. 2014;2:72-7 [Matushevskaia EV, Svirshchevskaia EV. Naftifin v terapii gribkovykh infektsii kozhi: 40 let uspekha. Vestnik dermatologii i venerologii. 2014;2:72-7 (in Russian)].
17. Котрехова Л.П., Разнатовский К.И., Вашкевич А.А. Особенности течения микозов кожи на современном этапе и их рациональная терапия. Consilium Medicum. Дерматология. 2014;1:31-4 [Kotrekhova LP, Raznatovskii KI, Vashkevich AA. Osobennosti techeniia mikozov kozhi na sovremennom etape i ikh ratsional'naia terapiia. Consilium Medicum. Dermatologiia. 2014;1:31-4 (in Russian)]. 
18. Gold JAW, Wu K, Jackson BR, Benedict K. Opportunities to improve guideline adherence for the diagnosis and treatment of onychomycosis: Analysis of commercial insurance claims data, United States. J Am Acad Dermatol. 2023;88(3):683-6. DOI:10.1016/j.jaad.2022.06.1201
19. Son JH, Doh JY, Han K, et al. Risk factors of dermatophytosis among Korean adults. Sci Rep. 2022;12(1):13444. DOI:10.1038/s41598-022-17744-5

________________________________________________

1. Seebacher C, Bouchara JP, Mignon B. Updates on the Epidemiology of Dermatophyte Infections. Mycopathologia. 2008;166:335-52. DOI:10.1007/s11046-008-9100-9
2. Leung AK, Barankin B, Lam JM, et al. Tinea pedis: an updated review. Drugs Context. 2023;12:2023-5-1. DOI:10.7573/dic.2023-5-1
3. Nussipov Y, Markabayeva A, Gianfaldoni S, et al. Clinical and Epidemiological Features of Dermatophyte Infections in Almaty, Kazakhstan. Open Access Maced J Med Sci. 2017;5(4):409-13. DOI:10.3889/oamjms.2017.124
4. Ziółkowska G, Nowakiewicz A, Gnat S, et al. Molecular identification and classification of Trichophyton mentagrophytes complex strains isolated fr om humans and selected animal species. Mycoses. 2015;58(3):119-26. DOI:10.1111/myc.12284
5. Deng R, Wang X, Li R. Dermatophyte infection: from fungal pathogenicity to host immune responses. Front Immunol. 2023;14:1285887. DOI:10.3389/fimmu.2023.1285887
6. Uhrlaß S, Verma SB, Gräser Y, et al. Trichophyton indotineae – An Emerging Pathogen Causing Recalcitrant Dermatophytoses in India and Worldwide – A Multidimensional Perspective. J Fungi (Basel). 2022;8(7):757. DOI:10.3390/jof8070757
7. Shaw D, Singh S, Dogra S, et al. MIC and Upper Lim it of Wild-Type Distribution for 13 Antifungal Agents against a Trichophyton mentagrophytes-Trichophyton interdigitale Complex of Indian Origin. Antimicrob Agents Chemother. 2020;64(4):e01964-19. DOI:10.1128/AAC.01964-19
8. Garcia-Rubio R, Cuenca-Estrella M, Mellado E. Triazole Resistance in Aspergillus Species: An Emerging Problem. Drugs. 2017;77(6):599-613. DOI:10.1007/s40265-017-0714-4
9. Gupta AK, Stec N, Summerbell RC, et al. Onychomycosis: a review. J Eur Acad Dermatol Venereol. 2020;34(9):1972-90. DOI:10.1111/jdv.16394
10. Sahni K, Singh S, Dogra S. Newer Topical Treatments in Skin and Nail Dermatophyte Infections. Indian Dermatol Online J. 2018;9(3):149-58. DOI:10.4103/idoj.IDOJ_281_17
11. Jiang Y, Luo W, Verweij PE, et al. Regional Differences in Antifungal Susceptibility of the Prevalent Dermatophyte Trichophyton rubrum. Mycopathologia. 2021;186(1):53-70. DOI:10.1007/s11046-020-00515-z
12. Rotta I, Ziegelmann PK, Otuki MF, et al. Efficacy of topical antifungals in the treatment of dermatophytosis: a mixed-treatment comparison meta-analysis involving 14 treatments. JAMA Dermatol. 2013;149(3):341-9. DOI:10.1001/jamadermatol.2013
13. Sahoo AK, Mahajan R. Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review. Indian Dermatol Online J. 2016;7(2):77-86.
DOI:10.4103/2229-5178.178099
14. Gupta AK, Ryder JE, Cooper EA. Naftifine: a review. J Cutan Med Surg. 2008;12(2):51-8. DOI:10.2310/7750.2008.06009
15. Vlahovic TC. The Role of Naftifine HCl 2% Gel and Cream in Treating Moccasin Tinea Pedis. J Drugs Dermatol. 2016;15(2 Suppl.):s56-9.
16. Matushevskaia EV, Svirshchevskaia EV. Naftifin v terapii gribkovykh infektsii kozhi: 40 let uspekha. Vestnik dermatologii i venerologii. 2014;2:72-7 (in Russian).
17. Kotrekhova LP, Raznatovskii KI, Vashkevich AA. Osobennosti techeniia mikozov kozhi na sovremennom etape i ikh ratsional'naia terapiia. Consilium Medicum. Dermatologiia. 2014;1:31-4 (in Russian). 
18. Gold JAW, Wu K, Jackson BR, Benedict K. Opportunities to improve guideline adherence for the diagnosis and treatment of onychomycosis: Analysis of commercial insurance claims data, United States. J Am Acad Dermatol. 2023;88(3):683-6. DOI:10.1016/j.jaad.2022.06.1201
19. Son JH, Doh JY, Han K, et al. Risk factors of dermatophytosis among Korean adults. Sci Rep. 2022;12(1):13444. DOI:10.1038/s41598-022-17744-5